sanofi blueprint medicines - Search News

News

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion

Drug Store News · 19h

Sanofi to acquire Blueprint Medicines for about $9.1B

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The Boston Globe · 3d

Sanofi to buy immunology biotech Blueprint for $9.1 billion

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.

The Wall Street Journal on MSN · 3d

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline

The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.

Chemistry World1d

Sanofi to buy Blueprint Medicines for over $9 billion

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

BioPharma Dive3d

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results